文献速递胸部肿瘤

纳武利尤单抗暴露与非小细胞肺癌治疗结局的相关性

Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-01-14

在76例二线接受纳武利尤单抗(3 mg/kg 每2周)治疗的非小细胞肺癌患者中,前瞻性采集血样、毒性及结局数据;缓解者(n=15)的谷浓度在2、4、10周时分别比进展者(n=33)高47%、53%、73%,较高谷浓度与更长总生存相关(p=0.001)。

要点

  • 缓解者纳武利尤单抗谷浓度在2周时比进展者高47%(p=0.001)。
  • 缓解者谷浓度在4周时比进展者高53%(p=0.008),10周时高73%(p=0.002)。
  • 较高谷浓度与更长总生存相关(p=0.001)。

核心结论

  • 对纳武利尤单抗有缓解的非小细胞肺癌患者其纳武利尤单抗暴露高于进展患者,提示可能存在暴露-反应关系。

研究设计与样本

  • 前瞻性收集2016年5月5日至2017年8月1日期间开始二线纳武利尤单抗治疗(3 mg/kg 每2周)的非小细胞肺癌患者的系列血样、毒性数据和结局数据,随访至2017年11月1日。
  • 共76例患者可评估分析;按实体瘤疗效评价标准1.1版的最佳总体缓解分类,毒性按常见不良事件评价标准分类。
  • 纳武利尤单抗谷浓度在治疗2、4和10周后测定(排除剂量延迟),计算几何均值,分别用方差分析和独立样本t检验与最佳总体缓解或毒性比较。
  • 比较高谷浓度组与低谷浓度组的总生存和无进展生存。

主要发现

  • 缓解者(n=15)平均谷浓度高于进展患者(n=33):2周后高47%(p=0.001),4周后高53%(p=0.008),10周后高73%(p=0.002)。
  • 较高谷浓度与更长总生存相关(p=0.001)。

关键数值与推荐

  • 缓解者(n=15)较进展者(n=33)谷浓度在2周后高47%(p=0.001)、4周后高53%(p=0.008)、10周后高73%(p=0.002)。
  • 较高谷浓度与更长总生存相关(p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步临床研究以阐明这些暴露-反应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nivolumab treatment is subject to large interpatient variability in both efficacy and toxicity, which may partly be explained by differences in nivolumab exposure. Exposure-response relationships in regular healthcare have not been extensively investigated for nivolumab. Therefore, we aimed to identify possible exposure-response relationships in nivolumab-treated patients with non-small-cell lung cancer (NSCLC). METHODS: Patients with NSCLC who started second-line nivolumab therapy (3 mg/kg Q2W) between May 5th 2016 and August 1st 2017, and from whom serial blood samples, toxicity data and outcome data were prospectively collected, were included. Follow-up was carried out until November 1st 2017. Patients were classified according to the best overall response (BOR) based on the Response Evaluation Criteria in Solid Tumours, v1.1, and toxicities according to the Common Terminology Criteria for Adverse Events. Nivolumab trough concentrations were measured after 2, 4 and 10 weeks of treatment, excluding dose delays, and calculated geometric means were tested versus BOR or toxicity using analysis of variance and an independent samples t-test, respectively. Overall survival (OS) and progression-free survival were compared between high and low trough concentration groups. RESULTS: Seventy-six patients were evaluable for analyses. Responders (n = 15) had higher mean trough concentrations than patients with progression (n = 33): 47% higher after 2 weeks (p = 0.001), 53% higher after 4 weeks (p = 0.008) and 73% higher after 10 weeks (p = 0.002). Higher trough concentrations were associated with longer OS (p = 0.001). CONCLUSIONS: This study shows that patients with NSCLC with a response to nivolumab had a higher nivolumab exposure than patients with progression, indicating a potential exposure-response relationship. Further clinical research should focus on clarifying these exposure-response relationships.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Basak EA, Koolen SLW, Hurkmans DP, et al. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. Eur J Cancer. 2019. PMID: 30654225. doi:10.1016/j.ejca.2018.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。